Yatiri Bio, a San Diego-based precision medicine company, has entered an exclusive global option to in-license agreement with South Korea's Oscotec for denfivontinib (SKI-G-801), a multikinase inhibitor, for the treatment of acute myeloid leukemia. Under the terms of the Oscotec in-license agreement, Yatiri Bio holds the exclusive option to license denfivontinib for development and commercialization worldwide. The deal was announced on March 24, 2026. Oscotec originated the compound and retains underlying ownership until the option is exercised.
Financial terms of the agreement were not disclosed. The option-to-license structure implies staged commitments, with an option exercise fee likely triggered at a future decision point tied to clinical or biomarker data. No upfront payment, milestone values, royalty rates, or equity components were made public. This is consistent with deal announcements from private, pre-revenue companies. The deal is indication-specific to AML, suggesting Oscotec retains rights to denfivontinib in other indications.
Deal context
Denfivontinib is a small molecule multikinase inhibitor targeting FLT3 and the CLK family of kinases. FLT3 is a receptor tyrosine kinase frequently mutated in AML and a validated therapeutic target. CLK kinases regulate RNA splicing, and their inhibition represents a less established but distinct mechanism in AML. The dual FLT3/CLK profile is what Yatiri Bio frames as the compound's differentiating feature. Oscotec completed a Phase I trial in relapsed/refractory AML (NCT03564288), enrolling 14 patients between 2018 and 2021. A separate Phase I trial in advanced solid tumors (NCT05971862) was conducted at Yonsei University in Seoul. No clinical data from either trial have been published in peer-reviewed journals. No US FDA regulatory designations have been reported for the compound.
Yatiri Bio plans to apply its proprietary ProteoCharts platform to identify a biomarker profile for denfivontinib AML treatment that extends beyond standard FLT3 mutation status. The platform uses deep neural networks to integrate proteomic profiling with clinical data and functional testing in patient-derived models. The company states it has identified a responder population that is FLT3-independent, potentially broadening the eligible patient pool beyond mutation-targeted therapies. Yatiri Bio intends to develop a laboratory determined test at its CLIA/CAP-accredited facility to stratify patients for upcoming trials. The company has described this as a capital-efficient approach to precision medicine oncology, designed to enrich trial enrollment with patients most likely to respond.